UK - Lectus Therapeutics closes £8.2m series A funding round

Lectus Therapeutics Ltd, a drug discovery and development company focusing on next-generation ion channel modulators, has announced that it has raised ТЃ8.2m in series A funding. The round was led by Sofinnova Partners, with Quester as a co-lead. Takeda Research Investment, Inc., the corporate venture arm of Takeda Pharmaceutical Company Ltd, also participated in the round, following up a seed investment made in April 2004 . Astellas Venture Management, the venture capital arm of Astellas Pharma Inc, also invested.